BioSpace News Archive

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Tempus, a leader in artificial intelligence and precision medicine, announced a multi-year collaboration that provides Kronos Bio with access to Tempus’ real-world genomic and transcriptomic data and data analytics tools.

Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 15, 2021 to report its second quarter 2021 financial results and provide a corporate update.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, announced that it proposes to offer $400.0 million aggregate principal amount of convertible senior notes due 2026, subject to market conditions and other factors.

Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, announced financial results for the third quarter of 2021 and highlighted recent corporate achievements.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Identifier: NCT04465890), demonstrated sustained HBsAg loss in CHB patients with baseline HBsAg ≤ 500 IU/mL.

Jiangsu Recbio Technology Co., Ltd. (“Recbio”), today announced preclinical data from its ReCOV a recombinant trimeric NTD and RBD two-component SARS-CoV-2 subunit vaccine adjuvanted with squalene-based adjuvant BFA03.